The Study of Treatment for the Inhibition of Cardiac Function due to Levobupivacine

DOI 19 References
  • Urashima Kazuya
    Department of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
  • Terai Shiori
    Department of Hygienic Chemistry, Osaka University of Pharmaceutical Sciences
  • Nishihori Takako
    Department of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
  • Hirotani Yoshihiko
    Department of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences
  • Tanaka Kazuhiko
    Department of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka University of Pharmaceutical Sciences

Bibliographic Information

Other Title
  • 局所麻酔薬レボブピバカインの心機能抑制に対する処置の検討

Search this article

Description

Levobupivacaine is a long acting, amide-type local anaesthetic that is the S(−)-isomer of the racemate bupivacaine. It has high affinity for the myocardial Na+ channel that can be cardiotoxic. So, an intravenous injection of levobupivacaine sometimes becomes a serious problem as the inhibition of cardiac function.<BR> Then, we investigated the effects of cardiac pacing and catecholamines(epinephrine, norepinephrine, isoproterenol) to treat the inhibition of cardiac function in isolated rat hearts.<BR> Our results showed that cardiac pacing and 0.8μg/kg/min epinephrine recovered the inhibition of cardiac function due to 5μg/ml levobupivacaine.

Journal

  • CIRCULATION CONTROL

    CIRCULATION CONTROL 25 (2), 169-175, 2004

    Japan Society of Circulation Control in Medicine

References(19)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top